Please register for Challenges and Solutions on Aggregates and Fragments Analysis by Size Exclusion Chromatography
When: Jun 19, 2019 12:00 PM EDT at:
Regeistration link: https://attendee.gotowebinar.
Sandeep Kondaveeti (Application Scientist, Agilent Technologies)
Veronica Qin (Application Scientist, Agilent Technologies)
Currently, hundreds of therapeutic monoclonal Antibodies (mAbs) and Antibody Drug Conjugates (ADCs) are in development, and many companies have multiple biomolecules in their pipelines. Aggregation of biotherapeutics is considered a high-risk Critical Quality Attribute (CQA) and monitored throughout the biomanufacturing process to ensure product safety and efficacy. While numerous techniques have been developed to monitor protein aggregation, size-exclusion chromatography (SEC) has been predominantly favored for routine analysis because of both its speed and reproducibility. In this webinar, we will demonstrate the benefit of SEC chromatography columns and their utility on intact analysis of biologics. Challenges including secondary interactions, column lifetime and throughput can be bottlenecks in SEC separation; recent advances in SEC column technology can offer inert surface and enhanced particle strength to achieve better performance. During the course of the webinar, there will be discussion regarding SEC column parameters and methods development for optimal performance and high throughput separations.
Key Learning Objectives:
o Native Mode analysis of mAbs and ADCs using SEC technique
o High-resolution, high-throughput aggregate and fragment analysis using sub 2 micron SEC technology
o Tips and tricks to optimize methods for intact analysis of biologics
After registering, you will receive a confirmation email containing information about joining the webinar.